<DOC>
	<DOCNO>NCT01045096</DOCNO>
	<brief_summary>The purpose study ass pharmacokinetics safety dexlansoprazole , daily ( QD ) , pediatric subject symptomatic Gastroesophageal Reflux Disease .</brief_summary>
	<brief_title>Study Evaluate Pharmacokinetics Safety Dexlansoprazole Pediatric Subjects With Symptomatic Gastroesophageal Reflux Disease</brief_title>
	<detailed_description>Gastroesophageal Reflux Disease ( GERD ) condition several cause result backward flow gastric content esophagus low esophageal sphincter . The prevalence GERD pediatric population increasingly become recognize document . It disease may persist adulthood , symptom older child adolescent similar see adult . Younger child generally present extra-esophageal manifestation , regurgitation , epigastric pain , old child adolescent typically present adult-type GERD symptom heartburn regurgitation . Treatment GERD aim improve symptom heal esophageal inflammation . Takeda Global Research &amp; Development Center , Inc. ( TGRD ) develop dexlansoprazole delayed release capsule new therapy treat acid relate disorder include symptomatic non-erosive GERD , heal erosive esophagitis ( EE ) maintenance heal EE . Dexlansoprazole delay release capsule study subject young 12 year age . This study design evaluate safety dexlansoprazole delay release capsule pediatric population ( 1 11 year old ) determine PK profile dexlansoprazole subject 1 11 year age similar adult give similar dose . Subjects satisfy screen evaluation Inclusion/Exclusion Criteria may enrol study . Eligible subject assign one three treatment group . Attempts make enroll equal number male female subject treatment group .</detailed_description>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Dexlansoprazole</mesh_term>
	<mesh_term>Lansoprazole</mesh_term>
	<criteria>Must body weight within 5th 95th percentile age , inclusive , determined National Center Health Statistics . Females childbearing potential must nursing , must negative serum pregnancy test Screening Visit Day 1 , sexually active agree routinely use adequate contraception Screening throughout duration study . Subjects take prescription nonprescription proton pump inhibitor ( PPI ) , histamine receptor antagonist ( except cimetidine ) , sucralfate , antacid regular require basis must agree discontinue usage Day 1 agree discontinue use throughout study . Must history GERD symptoms least 2 month prior Screening currently symptomatic , determined investigator . Must able swallow study drug capsule must able ingest study drug granule sprinkle 1 tablespoon applesauce . Has evidence current cardiovascular , central nervous system , pulmonary , endocrine disease , hepatic , hematopoietic , renal , metabolic dysfunction , serious allergy , asthma , allergic skin rash . Has know hypersensitivity PPI component formulation dexlansoprazole capsule . Is take prescription ( except birth control ) nonprescription medication ( include cimetidine ) , vitamin , dietary supplement within 10 day prior Day 1 , take herbal overthecounter medication within 28 day prior Day 1 . Has positive test result hepatitis B surface antigen hepatitis C virus antibody . Has donate lose great 10 % total blood volume , undergone plasmapheresis , transfusion blood product within 90 day prior first dose study drug . Has history alcohol abuse illegal drug use drug abuse past , test positive alcohol drug abuse initial Screening Visit Day 1 unwilling agree abstain alcohol drug throughout study . Has use product contain nicotine within 90 day prior first dose study drug positive cotinine screen initial Screening Visit Day 1 unwilling agree abstain throughout study . Is determined Cytochrome P450 2C19 poor metabolizer ( ie , genotyped homozygous nonwildtype ) .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Gastroesophageal Reflux</keyword>
	<keyword>Erosive Esophagitis</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pediatrics</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>